ClinicalTrials.gg
RecruitingNCT06627894ADEPT-ICUUpdated Dec 17, 2025

Attenuating DEPression With Internet CBT to Slow Cognitive Decline in Older ICU Survivors(ADEPT-ICU)

An interventional study of Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression and Active Control in Depression and Cognitive Decline, sponsored by Indiana University. Recruiting at 2 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Depression by Indiana University — 4 open to participants now, 4 under way, none of them phase 3. Depression · Indiana University.

Planned enrollment
9th of 32
300 · median 190
Started
2025
the only one that year
No phase
21 of 37
3 open now
Registered
35th of 37
by date

Among the 37 studies in Depression by Indiana University, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 21 with no phase, and was the 35th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

4 of the 37 studies in Depression by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Depression by Indiana University, or all of them as a file.
02

Study summary

Depression affects one-third of intensive care unit (ICU) survivors and represents a potentially modifiable target to slow cognitive decline and reduce the risk of Alzheimer's disease and related dementias (ADRD). Our multi-PI team proposes a two-arm RCT called ADEPT-ICU (Attenuating DEPression with Internet CBT to Slow Cognitive Decline in Older ICU Survivors), which will test the efficacy of an internet CBT intervention called Good Days Ahead (GDA) to reduce the burden of subjective cognitive decline (SCD) in older ICU survivors with moderate to severe depressive symptoms after ICU hospitalization.

Read the detailed description

Alzheimer's disease and related dementias (ADRD) affect 47 million people worldwide with an annual global cost of $818 billion. The risk of developing ADRD is disproportionately borne by older adults with multiple chronic conditions from underrepresented racial and ethnic groups (URGs). One such high risk group is older survivors of critical illness who were admitted to the intensive care units (ICUs). Nearly half of ICU survivors experience subjective cognitive decline(SCD), i.e., perceived decline in memory and thinking even with normal objective cognitive data. With over 5 million adult ICU admissions in the US each year, an intervention reducing SCD in older ICU survivors could significantly prevent or lower the incidence of ADRD. Thus, there is an urgent need for an inclusive randomized controlled trial (RCT) to rigorously test whether a novel, accessible, and scalable intervention can reduce SCD in a diverse cohort of older ICU survivors. One potential target for such interventions is post-ICU depression, which affects about one-third of ICU survivors. To date, there are no large scale RCTs which have rigorously tested whether depression focused psychotherapies, such as cognitive behavioral therapy (CBT), reduce SCD in a diverse cohort of older ICU survivors with depression.

We propose a two-arm, randomized, parallel-group, assessor-blinded clinical trial to evaluate the efficacy of internet CBT for depression compared to an active control in reducing SCD and slowing cognitive decline in older ICU survivors with post-ICU depression. The total duration of the intervention will be 6 months from randomization.

03

Conditions studied

  • Depression
  • Cognitive Decline

Keywords

  • Depression
  • Cognition
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 50 years of age and older
  2. Admitted to the intensive care for greater > 48 hours
  3. Able to understand and provide
  4. Elevated depressive symptoms, defined as Screening PHQ-9 or PHQ-8 ≥ 10 or Screening PHQ-9 or PHQ-8 = 5-9 with the presence a core symptom of anhedonia (PHQ-9 or PHQ-8 Item 1) or depressed mood (PHQ-9 or PHQ-8 Item 2)
  5. Willing to participate in cognitive testing
  6. Access to a telephone
  7. Discharge to home or an independent or assisted living facility
  8. Response is a 1,2, or 3 on PHQ-9 or PHQ-8 item 7, answered yes to "Have you experienced a change in your memory or other aspect of thinking in the past 1 to 3 years?", or score in the 25% percentile or lower on the (MOCA) based on normative data which account for age, gender, race, ethnicity and education.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of dementia or neurodegenerative disease (e.g. Alzheimer's disease, vascular dementia as per EHR and IQCODE, or Parkinson's disease) or on anti-dementia medications prior to ICU stay
  2. Diagnosis of severe mental illness (bipolar disorder, schizophrenia, schizoaffective) as per EHR and screening questions
  3. Persistent psychotic symptoms after ICU stay which would interfere with successful completion of intervention
  4. Recent or recurrent alcohol or substance use disorder as per HER and Drug Abuse Screening Test
  5. less than 1 year (e.g. terminal cancer diagnosis, discharged on hospice)
  6. Ischemic or hemorrhagic stroke, traumatic brain injury, or undergoing neurosurgery prior, during or after ICU stay
  7. Uncorrected visual or auditory impairment including legal blindness or deaf
  8. Status post tracheostomy and not able to communicate
  9. Incarcerated or on parole after ICU stay
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Intervention - Internet Cognitive-Behavioral Therapy (CBT) for Depression

    Participants will complete nine 45-minute sessions of an internet CBT for depression called Good Days Ahead (GDA; MindStreet, Inc.) with 20 minutes of therapist assistance per session on the phone over six months.

    Behavioral: Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression

  • Active comparator
    Active Control - Depression Education, Symptom Monitoring, and Usual Care

    Participants will review nine 45-minute segments of depression education material on their own with 20 minutes of therapist assistance per segment on the phone over six months. They will also have access to and could receive current depression care in the targeted healthcare systems.

    Behavioral: Active Control

Interventions

  • BehavioralTherapist-Assisted Internet Cognitive-Behavioral Therapy for Depression

    Good Days Ahead (MindStreet, Inc.)

  • BehavioralActive Control

    Depression education, symptom monitoring, and standard depression care

06

What researchers measure

Primary outcomes

  1. Subjective Cognitive Decline

    The primary outcome will be subjective cognitive decline (SCD), measured using the Cognitive Change Index self-report version (CCI-SR).

    Time frame: Measured at 6-month and 12-month follow-up.

Secondary outcomes

  1. Cognition status

    Repeatable Battery for Assessment of Neuropsychological Status (RBANS)

    Time frame: Measured at 6-month and 12-month follow-up.

  2. Quality of Life physical and mental component status

    Medical Outcome Study Short Form (SF-36)

    Time frame: Measured at 6-month and 12-month follow-up.

07

Study locations

2 of 2 sites recruiting
  • Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
  • IU Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2029, 55 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 55 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Oct 4, 2024
StartActual
Mar 13, 2025
Primary completionEst.
Oct 30, 2029
CompletionEst.
Oct 30, 2029
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06627894
Lead sponsor
Indiana University
Responsible party
Babar Khan, MD, MS (Professor of Medicine, Indiana University) — Principal investigator
First posted
Oct 4, 2024
Start date
Mar 13, 2025
Primary completion
Oct 30, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Dec 17, 2025

Study contacts

Babar Khan, MD, MS
Contact
bakhan@iu.edu
317-274-9132
Lori Rawlings, RN, BSN
Contact
rawlingl@regenstrief.org
317-274-9052
Babar Khan, MD, MS
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion